Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a study of REM0046127 oral suspension in mild to moderate Alzheimer's disease
2022-000080-43Phase 2Terminated
- Sponsor
- reMYND
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing REM0046127 oral suspension with Placebo oral suspension (2 arms). Primary endpoint: Incidence of treatment-emergent adverse events. Started Jun 2022; status: terminated.
02
Drugs
rem0046127
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2022-000080-43.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000080-43.